Morgan Stanley E Ffector Therapeutics, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.37 - $0.69 $6,660 - $12,419	18,000 New	18,000 $8,000
Q4 2023 Feb 13, 2024	SELL	$0.37 - $0.69 $710 - $1,324	-1,920 Reduced 9.64%	18,000 $8,000
Q3 2023 Nov 15, 2023	BUY	$0.49 - $0.88 $940 - $1,689	1,920 Added 10.67%	19,920 $11,000
Q2 2023 Aug 14, 2023	BUY	$0.35 - $1.39 $6,300 - $25,020	18,000 New	18,000 $14,000
Q4 2022 Feb 14, 2023	SELL	$0.38 - $0.66 $0 - $0	-1 Reduced 0.02%	6,000 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.08 - $1.41 $99 - $1,759	-1,248 Reduced 17.22%	6,001 $3,000
Q2 2022 Oct 27, 2022	BUY	$1.3 - $3.84 $9,344 - $27,601	7,188 Added 11783.61%	7,249 $10,000
Q2 2022 Aug 15, 2022	BUY	$1.3 - $3.84 $9,344 - $27,601	7,188 Added 11783.61%	7,249 $10,000
Q1 2022 Oct 27, 2022	SELL	$3.85 - $8.2 $27,673 - $58,941	-7,188 Reduced 99.16%	61 $0
Q1 2022 May 13, 2022	SELL	$3.85 - $8.2 $110,175 - $234,659	-28,617 Reduced 99.79%	61 $0
Q4 2021 Feb 14, 2022	BUY	$5.71 - $13.15 $163,180 - $375,800	28,578 Added 28578.0%	28,678 $237,000
Q3 2021 Nov 15, 2021	BUY	$8.56 - $27.17 $856 - $2,717	100 New	100 $1,000

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.